QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Schlenk, R; Dombret, H; Amadori, S; Montesinos, P; Levis, M; Sekeres, MA; Cortes, J; Perl, A; Zernovak, O; Mires, D; Ge, N; Zhang, H; Hanyok, J; Macintyre, S; Gokmen, S; Kobayashi, K; Erba, H

Published Date

  • September 1, 2017

Published In

Volume / Issue

  • 28 /

Published By

Pages

  • 1

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

International Standard Serial Number (ISSN)

  • 0923-7534

Conference Name

  • 42nd European-Society-for-Medical-Oncology Congress (ESMO)

Conference Location

  • Madrid, SPAIN

Conference Start Date

  • September 8, 2017

Conference End Date

  • September 12, 2017